Ignyta Inc. (RXDX)

26.95 0 (0%)

IEX Real-Time Price

February 8, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 26.95

Price Open 26.95

Volume: 498,855

Avg Volume: 3.21M

Market Cap: 1.82B

P/E Ratio -9.98

52 Wk Range 5.8-27.1



RXDX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-01-12
66.83M
3.06M
0.59
4.57%

2017-12-29
67.02M
2.4M
0.69
3.59%

2017-12-15
67.02M
4.63M
5.22
6.90%

2017-11-30
65.77M
4.12M
4.09
6.26%




RXDX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-03-13
Q4 2017
N/A
-0.44 (3)
0.00
0.00

2017-11-07
Q3 2017
N/A
-0.56 (2)
-0.51
0.05

2017-08-08
Q2 2017
N/A
-0.61 (2)
-0.56
0.05

2017-05-01
Q1 2017
AMC
-0.70 (2)
-0.96
-0.26

News

Solid Biosciences slips (2018-01-30 12:10 SeekingAlpha)

Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A…

 

Ignyta (RXDX) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow (2018-01-10 13:37 SeekingAlpha)

The following slide deck was published by Ignyta, Inc. in conjunction with this Read more …

 

Ignyta to Present at 36th Annual J.P. Morgan Healthcare Conference (2018-01-04 07:00 Business Wire)

Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 36 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 201…

 

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to Shareholders (2018-01-03 12:35 Business Wire)

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc. (Ignyta or the Company) (NASDAQ CM: RXDX) stock prior to December 22, 2017 . You are hereby notified that Levi…

 

Your Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For Phase 3 Trial, Avadel Provides Update (2017-12-31 09:42 SeekingAlpha)

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss the latest update from Progenics Pharmaceuticals ( PGNX ), which sparked a rally in pre-market trading on Friday . Progenics announced that the FDA has accepted for review its New Drug Application (NDA) for Azed…

 


Statistics

Shares Outstanding: 67.59M

Top 15 Institution Percent: 87.00

Price To Sales: N/A

Price To Book: 20.70

Revenue: N/A

Gross Profit: N/A

Cash: 522.15M

Debt: 31.12M

Return On Assets: -72.79

Return On Equity: -119.97

Profit Margin: N/A

Price History

Beta: 1.62

50-day Moving Avg: 22.91

200-day Moving Avg: 13.85

YTD Change: 0.00

5-day Change: 0.00

1-month Change: -0.19

3-month Change: 68.44

6-month Change: 159.76

1-year Change: N/A

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Ignyta Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.ignyta.com

Ignyta Inc is a precision oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. It aims to develop and commercialize molecularly targeted therapies.